Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.35M Buy
26,444
+329
+1% +$38.5K 0.31% 55
2026
Q1
$2.96M Buy
26,115
+117
+0.5% +$13.5K 0.29% 64
2025
Q4
$2.97M Sell
25,998
-9,573
-27% -$899K 0.33% 52
2025
Q3
$2.95M Buy
35,571
+1,074
+3% +$88.5K 0.27% 63
2025
Q2
$2.82M Buy
34,497
+6,070
+21% +$482K 0.22% 86
2025
Q1
$2.48M Buy
28,427
+15,626
+122% +$1.46M 0.23% 89
2024
Q4
$1.27M Buy
+12,801
New +$1.32M 0.16% 107

Other funds holding MRK

Armis Advisers's MRK Position: Q2 2026 in Review

Armis Advisers increased its Merck (MRK) stake by 1.3% in Q2 2026, buying an estimated $38.5K and bringing the position to 26,444 shares worth $3.35M. The position accounts for 0.31% of the portfolio, ranked #55.

Armis Advisers first reported a position in MRK in Q4 2024 and has held it in 7 quarters since. 711 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Armis Advisers held 26,444 shares of Merck worth $3.35M as of Q2 2026.
  • Armis Advisers bought 329 Merck shares in Q2 2026, an estimated $38.5K.
  • Merck made up 0.31% of Armis Advisers's portfolio in Q2 2026, its #55 holding.
  • Armis Advisers first reported a position in Merck in Q4 2024 and has held it in 7 quarters since.
  • 711 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Armis Advisers's 13F filing for Q2 2026, filed 7 Jul 2026.